Zuckerman Investment Group LLC Sells 2,010 Shares of Becton, Dickinson and Company (BDX)

Zuckerman Investment Group LLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,005 shares of the medical instruments supplier’s stock after selling 2,010 shares during the quarter. Becton, Dickinson and makes up 2.4% of Zuckerman Investment Group LLC’s portfolio, making the stock its 18th largest holding. Zuckerman Investment Group LLC’s holdings in Becton, Dickinson and were worth $9,603,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and in the 1st quarter worth approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 240 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in Becton, Dickinson and by 8.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after buying an additional 51 shares in the last quarter. Harfst & Associates Inc. grew its holdings in Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 221 shares in the last quarter. Finally, Financial Architects Inc grew its holdings in Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after buying an additional 54 shares in the last quarter. 88.46% of the stock is owned by institutional investors.

Becton, Dickinson and Company (NYSE BDX) traded up $0.15 on Wednesday, reaching $219.07. The company’s stock had a trading volume of 963,700 shares, compared to its average volume of 1,319,580. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $229.68. The firm has a market capitalization of $49,909.01, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter in the prior year, the firm earned $2.12 EPS. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. research analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date of this dividend is Thursday, December 7th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s dividend payout ratio is 62.80%.

In other news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

A number of equities analysts recently issued reports on BDX shares. Royal Bank Of Canada reissued a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research downgraded Becton, Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Stifel Nicolaus restated a “buy” rating and issued a $245.00 target price on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley upped their target price on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Finally, Wells Fargo & Company restated a “positive” rating and issued a $235.00 target price (up from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $217.08.

TRADEMARK VIOLATION NOTICE: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://ledgergazette.com/2017/12/06/zuckerman-investment-group-llc-sells-2010-shares-of-becton-dickinson-and-company-bdx.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply